Actividad Investigadora
Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial
Autores de IDIVAL
Autores ajenos al IDIVAL
- Ortiz-Romero PL
- Maroñas Jiménez L
- Muniesa C
- Estrach T
- Servitje O
- Fernández-de-Misa R
- Gallardo F
- Sanmartín O
- Riveiro-Falkenbach E
- Vega R
- Lora D
- Postigo C
- Jiménez B
- Sánchez-Beato M
- Rodríguez Peralto JL
- de la Cámara AG
- de la Cruz J
- Piris Pinilla MÁ
Unidades
Abstract
Background The calcineurin pathway is often activated in mycosis fungoides. We aimed to assess the activity and safety of topical pimecrolimus, a calcineurin inhibitor, in patients with early mycosis fungoides. Methods PimTo-MF was a single-arm, multicentre, phase 2 trial done at six medical centres in Spain. Patients (aged >= 18 years) had histologically confirmed early mycosis fungoides (stages IA-IIA) and an Eastern Cooperative Oncology Group performance status of 0-1. Key exclusion criteria induded the use of concurrent treatments for mycosis fimgoides, including sunbathing, topical or systemic corticosteroids, and other calcineurin inhibitors. Patients applied topical pimecrolimus 1% cream on their skin lesions twice daily for 16 weeks (1 g per 2% of body surface), with subsequent follow-up of 12 months. Dosage modifications were not allowed. To evaluate adherence to the treatment, patients were instructed to return all empty tubes to the hospital (as per drug accountability protocols). The primary endpoint was the overall response ratein the intention-to-treat population. PimTo-MF is registered with EudraCT, 2014-001377-14, and is complete. Findings Between March 1, 2015, and Sept 30, 2016, 39 patients were enrolled. All patients were assessable, with a median age of 51.5 years (IQR 45-62), and the population was predominantly male (24 male [62%],15 female [38%]). Median follow-up after baseline was S-7 years (IQR 5.7-6.2). 22 (56%) of 39 patients had an overall response (one complete response, 21 partial responses). Responses were observed across IA (14 [54%] of 26 patients) and IB (eight [73%] of 11 patients) clinical stages, but not IIA. Topical pimecrolimus was well tolerated and no patient required a dose reduction or discontinued treatment because of unacceptable drug-related toxicity. No patients were lost to follow-up or discontinued treatment. 13 (33%) of 39 patients reported adverse events; transitory mild burning or pruritus (grade 1) was the most common, seen in eight (21%) patients. In three (8%) of these patients, the burning or pruritus was considered related to treatment. No grade 4 or 5 adverse events were observed. Interpretation Pimecrolimus 1% cream seems active and safe in patients with early stage mycosis fungoides. Our findings should be taken with caution until long-term follow-up data are obtained that confirm the safety of this treatment. Further controlled clinical trials are warranted to confirm these results. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 2352-3026, 2352-3026
- Tipo:
- Article
- Páginas:
- 425-433
- PubMed:
- 35654076
- Enlace a otro recurso:
- www.sciencedirect.com
Lancet Haematology ELSEVIER SCI LTD
Citas Recibidas en Web of Science: 11
Documentos
- No hay documentos